|Bid||0.01 x 2200|
|Ask||14.45 x 900|
|Day's Range||11.74 - 11.90|
|52 Week Range||10.81 - 18.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.83|
HOPKINTON, Mass. and NEW YORK, Aug. 08, 2018-- Spring Bank Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering ...
Spring Bank Pharmaceuticals, Inc. (SBPH) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Spring Bank. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Spring Bank intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering. Spring Bank intends to use the net proceeds from this offering to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.
Spring Bank Pharmaceuticals, Inc. (SBPH) today announced positive results from the third cohort (inarigivir 100mg) of Part A of the ongoing Phase 2 ACHIEVE trial. Spring Bank also announced the expansion of the Phase 2 clinical trial being undertaken by Gilead Sciences, Inc. to include up to two additional cohorts of inarigivir co-administered with tenofovir alafenamide 25mg in chronic hepatitis B patients. Spring Bank is developing inarigivir, an orally-administered investigational selective immunomodulator, as a potential backbone in a combinatorial treatment for chronic hepatitis B virus (HBV), with a goal to accelerate and substantially increase functional cure rates in a simple, safe and selective manner. Spring Bank has already randomized the majority of the patients in the fourth and final cohort (inarigivir 200mg) of the ACHIEVE trial and anticipates that it will have top-line results by the end of 2018.
Conference Call Scheduled for Thursday, August 2 at 8:00 a.m. EDT to Provide Corporate Update. HOPKINTON, Mass., Aug. 01, 2018-- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company ...
HOPKINTON, Mass., May 29, 2018-- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases ...
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPHT as the Company's latest news hit the wire. On May 01, 2018, the New York-based biopharmaceutical Company announced that it has completed patient enrollment in its Phase-2a clinical trial of Zimura® (avacincaptad pegol) in patients with wet age-related macular degeneration (AMD).
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at ...